Detailed Narrative
Q2 & H1 FY26 Financial Performance Overview
Excel Industries reported a challenging Q2 FY26 with revenues of ₹270 crores, a sequential decline from ₹310 crores in Q1 FY26. This led to a 29% sequential drop in EBITDA to ₹30 crores and a PAT of ₹19 crores. For the first half of FY26, net operating revenue stood at ₹580 crores, marking a 9% increase over H1 FY25's ₹534 crores. However, H1 FY26 EBITDA was ₹72 crores (down from ₹88 crores in H1 FY25) and PAT was ₹52 crores (a 20% decline from H1 FY25).
Strategic Initiatives and New Contracts
The company has signed a binding term sheet for a new contract manufacturing line for a specialty chemical, involving a ₹40 crore investment and expected to generate ₹35-40 crores in annual revenue (excluding raw materials) by June 2026. This project is EBITDA accretive and aims to reduce dependence on the agrochemical sector. Additionally, a capacity expansion for a key biocide product has been commissioned, projected to add ₹15 crores in full-year revenue. Initial supplies have also commenced under a long-term supply arrangement with a multinational company.
Agrochemical Segment Challenges and Outlook
The agrochemical segment, which constitutes 50-60% of revenues, faced subdued demand in Q2 FY26 due to an extended monsoon season, disrupting agronomic cycles and leading to low demand. This resulted in a 15-20% increase in inventory levels from the previous quarter. Management expects Q3 FY26 to be a lean quarter for this segment but anticipates normalization of demand and inventory clearance by Q4 FY26 or slightly later, contingent on a better winter crop cycle.
Capital Expenditure Plans
Excel Industries plans a total CAPEX of ₹200-300 crores over the next three years, encompassing both maintenance and growth initiatives. The ₹40 crore investment for the new contract manufacturing line is part of this broader plan. The company also noted that its current capacity utilization is 70-75%, with effective maximum utilization for chemical plants typically ranging from 85-90%, leaving some headroom for growth.
R&D and Innovation Focus
The new R&D center, launched last year, is on track to become operational in Q3 FY26. This facility is central to the company's commitment to innovation, product development, and long-term value creation. The R&D strategy focuses on multi-step synthesis, backward integration, and developing products that align with technology assets and strong financial parameters, aiming to strengthen existing business areas and diversify the portfolio.
Business Segment Contribution and Diversification
The company's revenue breakdown includes agrochemical intermediates (50-60%), performance solutions (25-30%), pharma intermediates and APIs (6-8%), yellow phosphorus derivatives (7-10%), and waste management (1%). The strategic focus on contract manufacturing and performance solutions aims to build a resilient, future-ready organization by leveraging core strengths and reducing reliance on the agrochemical sector, with new projects contributing an estimated ₹60 crores at peak.